[89Zr]Df-IAB2M

RADIATION3 trials

Sponsors

ImaginAb, Inc.

Conditions

Metastatic Prostate CancerProstate Cancer

Phase 1

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

CompletedNCT01923727

ImaginAb, Inc.Metastatic Prostate Cancer

Start: 2013-08-31End: 2016-06-30Updated: 2020-02-13

Phase 2

Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy

CompletedNCT02349022

ImaginAb, Inc.Prostate Cancer

Start: 2015-01-31End: 2016-07-31Updated: 2020-02-13

A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer

WithdrawnNCT02424513

ImaginAb, Inc.Prostate Cancer

Start: 2015-03-31End: 2016-03-31Updated: 2015-06-02

Related Papers

A phase I/IIa trial of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging with <sup>89</sup>Zr-Df-IAB2M in metastatic prostate cancer (PCa).

Journal of Clinical Oncology2016-01-103 citations

Pathologic correlation of <sup>89</sup>Zr-Df-IAB2M antiprostate-specific membrane antigen (PSMA) minibody in patients with metastatic prostate cancer.

Journal of Clinical Oncology2015-03-011 citations